Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 2 (2)

Trial Status

Not Yet Recruiting2
Recruiting1
Active Not Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07554508Not Yet RecruitingPrimary

Belzutifan VHL RCC HK Prospective Registry

NCT03401788Phase 2Active Not RecruitingPrimary

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

NCT07171905Phase 2RecruitingPrimary

CAT-VHL Exploring the Role of Carbonic Anhydrase IX as Diagnostic and Theranostic Target in Von-Hippel Lindau Disease

NCT07275099Not Yet RecruitingPrimary

Quality of Life, Psychological Impact, and Care-related Challenges in Patients Affected by Von Hippel-Lindau Syndrome.

Showing all 4 trials

Research Network

Activity Timeline